FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

	transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						
1. Name and Address of Reporting $Person^\star$							

1. Name and Address Cannon Kara	of Reporting Person *		2. Issuer Name and Ticker or Trading Symbol <u>ENZO BIOCHEM INC</u> [ENZ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) C/O ENZO BIOCH	(First) HEM, INC.	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/21/2024	X	Director Officer (give title below) Chief Executive C	10% Owner Other (specify below) Officer		
81 EXECUTIVE BLVD., SUITE 3			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) FARMINGDALE		11735		X	Form filed by One Reporting Form filed by More than On	-		
(City)	(State)	(Zip)						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								

6. Ownership Form: Direct (D) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 7. Nature of 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 5. Amount of Date Execution Date, Transaction Securities Indirect Beneficially Owned (Month/Dav/Year) if anv Code (Instr. or Indirect (I) Beneficial 8) (Month/Day/Year Following Reported (Instr. 4) Ownership (Instr. 4) Transaction(s) (A) or (D) (Instr. 3 and 4) Code v Amount Price Common Stock 02/21/2024 Μ 10,640(1) \$<mark>0</mark> 307,120 D Α Common Stock 02/21/2024 F 5,823(2) D \$<mark>0</mark> 301,297 D Α D Common Stock 02/23/2024 150,000(3) A **\$**0 451,297 45,065 T 401k Common Stock

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		Transaction Code (Instr.		Derivative		(Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		 9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Transaction(s) (Instr. 4)		

Explanation of Responses:

1. Represents shares issued, on February 21, 2024, for no consideration pursuant to a Performance Share Award that vested in full on November 3, 2023.

2. Represents shares withheld by Enzo Biochem, Inc. upon the issuance of the shares described in Footnote 1 above to satisfy tax withholding requirements.

3. The Reporting Person was granted Restricted Stock Units that will fully vest, subject to the individual's continued employment with Enzo Biochem, Inc, in three equal annual installments over the course of three years, commencing on the first anniversary of the grant date; provided, that, they shall vest in full earlier upon the occurrence of a Change of Control.

<u>/s/ Kara Cannon</u> ** Signature of Reporting Person 02/27/2024 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.